<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20266" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dawn Phenomenon</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>O'Neal</surname>
            <given-names>Teri B.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Luther</surname>
            <given-names>Euil E.</given-names>
          </name>
          <aff>LSUHSC - Shreveport/Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Teri O'Neal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Euil Luther declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20266.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The "dawn phenomenon" refers to periodic episodes of hyperglycemia experienced by patients with diabetes in the early morning hours. This clinical entity differs from the Somogyi effect in that it is not preceded by an episode of hypoglycemia. This activity will describe the disease process, outline an appropriate evaluation strategy, and review treatment options for the dawn phenomenon. It will also explain the importance of an interprofessional approach to evaluation and education for optimizing control of the patient affected by the dawn phenomenon.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the patient populations affected by the dawn phenomenon as well as the prevalence of this abnormality.</p></list-item><list-item><p>Explain the pathophysiologic processes that produce the dawn phenomenon and the reasons that patients without diabetes are not affected.</p></list-item><list-item><p>Outline a diagnostic evaluation for the dawn phenomenon that includes the use of continuous glucose monitoring systems.</p></list-item><list-item><p>Summarize the importance of a collaborative approach to diagnosis and management for the dawn phenomenon, with the aim of improving outcomes for patients as far as glycemic control and thereby prevention of long term adverse events.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20266&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20266">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20266.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The &#x0201c;dawn phenomenon&#x0201d; refers to periodic episodes of hyperglycemia occurring in the early morning hours. Originally described in the early 1980s by Schmidt et al.<xref ref-type="bibr" rid="article-20266.r1">[1]</xref>, the dawn phenomenon differs from the Somogyi effect in that it is not preceded by an episode of hypoglycemia. Understanding and differentiating between these two clinical entities becomes critical in the optimal management of diabetes.<xref ref-type="bibr" rid="article-20266.r2">[2]</xref></p>
      </sec>
      <sec id="article-20266.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Diurnal variation in hepatic glucose metabolism has been well documented.&#x000a0; The transient increase in both glycogenolysis and gluconeogenesis in the early morning hours can be responsible for hyperglycemia if unopposed by insulin.<xref ref-type="bibr" rid="article-20266.r3">[3]</xref><xref ref-type="bibr" rid="article-20266.r4">[4]</xref><xref ref-type="bibr" rid="article-20266.r5">[5]</xref></p>
      </sec>
      <sec id="article-20266.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The dawn phenomenon, and more recently, the extended dawn phenomenon (persistence of hyperglycemia into the later morning hours), have been studied extensively with numerous articles published on the subject. Both entities are responsible for morning glucose elevations, which are&#x000a0;difficult to control. The dawn phenomenon has been documented in both type 1 and type 2 diabetes and has been demonstrated in all age groups, even patients with type 2 diabetes over 70 years of age. For both type 1 and type 2 diabetes mellitus, its prevalence is estimated to exceed 50 percent.<xref ref-type="bibr" rid="article-20266.r6">[6]</xref>&#x000a0;This affects a large patient population over a wide age range, and the dawn phenomenon should be an important consideration for any clinician who manages patients with diabetes.</p>
      </sec>
      <sec id="article-20266.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Studies in populations without diabetes have shown that blood glucose, and plasma insulin levels remain steady through the night, with only a small increase in insulin secretion before dawn, which serves to achieve supression of the hepatic glucose production. Hyperglycemia is prevented by this physiologic surge of insulin. Hence, the dawn phenomenon does not occur in patients without&#x000a0;diabetes because they can secrete normal amounts of insulin to prevent it. In&#x000a0;patients without diabetes growth hormone exerts insulin-antagonistic effects.&#x000a0;<xref ref-type="bibr" rid="article-20266.r7">[7]</xref> Furthermore, exogenous insulin activity frequently begins to wane during the early morning hours (depending on the type of&#x000a0;insulin and route of administration), so there is not enough opposition to hepatic activity to prevent hyperglycemia.&#x000a0;Patients with type 2 diabetes are more likely affected by early morning dysregulation of hepatic glucose production because of the inability to produce compensatory insulin secretion.<xref ref-type="bibr" rid="article-20266.r2">[2]</xref><xref ref-type="bibr" rid="article-20266.r8">[8]</xref></p>
      </sec>
      <sec id="article-20266.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with diabetes will manifest the dawn phenomenon clinically with persistent and worsening early morning hyperglycemia, which is difficult to control. Often found early in the disease process, this is associated with worsening HbA1c levels. &#x000a0;The dawn phenomenon is not associated with nocturnal hypoglycemic episodes, and no specific physical findings are present.</p>
      </sec>
      <sec id="article-20266.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of the dawn phenomenon is most effectively&#x000a0;achieved by the use of continuous glucose monitoring (CGM), which in recent years has become more widely available to clinicians.<xref ref-type="bibr" rid="article-20266.r9">[9]</xref><xref ref-type="bibr" rid="article-20266.r10">[10]</xref>&#x000a0;In addition to documenting elevated early morning glucose levels, CGM ensures no associated nocturnal episodes of hypoglycemia have occurred, which could indicate a Somogyi effect rather than a true dawn phenomenon. The dawn phenomenon is quantified by subtracting the overnight glucose nadir from the glucose value observed just before breakfast. An alternative to CGM has been described by Monnier et al., utilizing intermittent glucose monitoring to quantify the magnitude of the dawn phenomenon.&#x000a0;&#x000a0;A strong correlation between pre-meal glucose values and the change in glucose with the dawn phenomenon has been identified. This has enabled the development of a formula to calculate the magnitude of early morning hyperglycemia without CGM.<xref ref-type="bibr" rid="article-20266.r11">[11]</xref> By measuring blood glucose pre-breakfast, pre-lunch, and pre-dinner, then taking the difference between the pre-breakfast glucose and the average of the pre-lunch and pre-dinner glucose values to determine &#x0201c;X&#x0201d;, the presence of&#x000a0;the dawn phenomenon in an individual, which has been defined as an upward variation in glucose of 20 mg/dl, can be detected with 71% sensitivity and 68% specificity. The magnitude of the dawn phenomenon can then be calculated by using the equation 0.49X +15.<xref ref-type="bibr" rid="article-20266.r11">[11]</xref></p>
      </sec>
      <sec id="article-20266.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>When the presence of the dawn phenomenon is detected, especially when associated with the extended dawn phenomenon, an individual patient should be considered for earlier and more aggressive control of glucose.&#x000a0; The prevention of long-term sequelae by minimizing exposure to hyperglycemia is key early in the disease process. Optimal insulin therapy is important in type 1 diabetes, but also in type 2 diabetes. Oral hypoglycemic agents have failed to show adequate control of the dawn phenomenon, while insulin therapy has been shown to be much more effective.&#x000a0;</p>
        <p>Choosing an insulin regimen must, of course, be individualized for each patient, but research has indicated that the presence of&#x000a0;the dawn phenomenon must be considered in selecting the type of&#x000a0;insulin and the mechanism of delivery.&#x000a0; In studies that have demonstrated superior glycemic control with continuous insulin infusion as opposed to long-acting insulin formulations, the dawn phenomenon is likely the reason. The ability for a continuous infusion to provide a bolus in the early morning hours to counteract the dawn phenomenon is a possible explanation, as long-acting insulin preparations have no ability to achieve this. For type 1 diabetes, tight control with insulin must take into account the dawn phenomenon to avoid nocturnal hypoglycemia before the onset of early morning glucose elevations. If insulin adjustments are made based on early morning fasting glucose levels, a larger dose of insulin might be administered than would be appropriate if the dawn phenomenon magnitude was considered.<xref ref-type="bibr" rid="article-20266.r12">[12]</xref></p>
        <p>Management of morning hyperglycemia should be a part of the overall diabetes control strategy.&#x000a0; Lifestyle modification is an important component to be considered.&#x000a0; Better control of morning glucose levels has been demonstrated by increasing the amount of exercise in the evening and by increasing the protein to carbohydrate ratio of the evening meal. Consuming breakfast is also very important.&#x000a0;While it seems counterintuitive, an early morning meal serves to decrease the secretion of insulin-antagonistic hormones.<xref ref-type="bibr" rid="article-20266.r13">[13]</xref><xref ref-type="bibr" rid="article-20266.r2">[2]</xref>&#x000a0;In recent study the use of acarbose helped with dawn phenomenon treatment, but not the use of sulfonylurea.<xref ref-type="bibr" rid="article-20266.r14">[14]</xref></p>
      </sec>
      <sec id="article-20266.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The dawn phenomenon is known for early morning hyperglycemia.&#x000a0; Other considerations for this clinical presentation must include the Somogyi effect as well as poor glycemic control.<xref ref-type="bibr" rid="article-20266.r2">[2]</xref>&#x000a0;</p>
        <p>The Somogyi effect (still a matter of debate for some authorities) is the development of rebound hyperglycemia after an episode of hypoglycemia, often induced by excess insulin or inadequate calorie intake with insulin therapy. Exclusion of overnight hypoglycemia by the use of continuous glucose monitoring (CGM) is an effective way of ruling this out when evaluating early morning hyperglycemia. When CGM is not available, a fingerstick in early morning hours (between 2-3 am) is recommended and it can provide guidance on the trend of the glucose levels.</p>
        <p>Poor glycemic control in the overall picture of diabetes is evident by the persistent elevation of blood glucose levels, without an obvious prominence of early morning hyperglycemia.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-20266.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The importance of recognition and control of the dawn phenomenon in type 2 diabetes lies in preventing additional exposure to elevated blood glucose levels, thereby&#x000a0;preventing increasing insulin resistance. The increasing defect in insulin secretion and sensitivity has been shown to produce a steady decline in the quality of normal glucose metabolism over the life course of the disease.<xref ref-type="bibr" rid="article-20266.r15">[15]</xref>&#x000a0;Additional data from Monnier et al., has indicated that the dawn phenomenon could affect the overall glycemic control in type 2 diabetes, elevating the HbA1c levels by as much as 0.4%.<xref ref-type="bibr" rid="article-20266.r9">[9]</xref></p>
      </sec>
      <sec id="article-20266.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Epidemiological analyses have provided information that a 1% increase in A1c can be associated with a 15%-20% increased risk of cardiovascular complications.<xref ref-type="bibr" rid="article-20266.r16">[16]</xref> Additionally, a 2012 study reported by researchers from Sweden indicated that a 0.8% reduction in A1c could produce a cardiovascular death risk reduction as high as 45%.<xref ref-type="bibr" rid="article-20266.r17">[17]</xref>&#x000a0;Controlling the dawn phenomenon alone could achieve as much as half the A1c improvement needed for this benefit, and since it is felt to be one of the earliest disorders in the natural progression of type 2 diabetes, it should be taken into consideration as an indicator for more aggressive therapy early in the disease.</p>
      </sec>
      <sec id="article-20266.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with diabetes should receive extensive education in all aspects of the disease, with emphasis on dietary and medication management, as well as the importance of exercise and awareness of the potential consequences of the disease.&#x000a0; Specific information regarding the dawn phenomenon should be provided if the patient is suspected or has been diagnosed with this entity.&#x000a0; The importance of using dietary interventions to minimize the dawn phenomenon should be discussed at length.&#x000a0; Recommendations should include increasing protein to carbohydrate ratio for the evening meal and encouraging the patient to have breakfast regularly.&#x000a0; Increased physical activity during the evening hours has also demonstrated some effectiveness in minimizing early morning hyperglycemia.<xref ref-type="bibr" rid="article-20266.r2">[2]</xref></p>
      </sec>
      <sec id="article-20266.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diabetes nurse educators,&#x000a0;dieticians, and clinicians must be skilled at the recognition of the dawn phenomenon. An interprofessional team approach in managing patients with this problem will result in the best outcomes. [Level V]&#x000a0; Communication between all members of the team is important to maximize benefit from needed lifestyle changes, self-monitoring of the disease, and medication adjustments.&#x000a0; Presenting a "united front", the interprofessional team can convey a strong message to the patient about the importance of controlling the dawn phenomenon in the context of their diabetes.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-20266.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20266&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20266">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/diabetes/dawn-phenomenon/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20266">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20266/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20266">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20266.s15">
        <title>References</title>
        <ref id="article-20266.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Hadji-Georgopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rendell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kowarski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation.</article-title>
            <source>Diabetes Care</source>
            <year>1981</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>579</fpage>
            <page-range>579-85</page-range>
            <pub-id pub-id-type="pmid">6751733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rybicka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krysiak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okopie&#x00144;</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia.</article-title>
            <source>Endokrynol Pol</source>
            <year>2011</year>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>276</fpage>
            <page-range>276-84</page-range>
            <pub-id pub-id-type="pmid">21717414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boden</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Urbain</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production.</article-title>
            <source>Diabetes</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1044</fpage>
            <page-range>1044-50</page-range>
            <pub-id pub-id-type="pmid">8690150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perriello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pampanelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Del Sindaco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lalli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ciofetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Santeusanio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brunetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bolli</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM.</article-title>
            <source>Diabetes</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>1010</fpage>
            <page-range>1010-6</page-range>
            <pub-id pub-id-type="pmid">9166673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radziuk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pye</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?</article-title>
            <source>Diabetologia</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>1619</fpage>
            <page-range>1619-28</page-range>
            <pub-id pub-id-type="pmid">16752180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Schade</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>The dawn phenomenon revisited: implications for diabetes therapy.</article-title>
            <source>Endocr Pract</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-64</page-range>
            <pub-id pub-id-type="pmid">16033737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Bolli</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Cryer</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Gerich</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion.</article-title>
            <source>N Engl J Med</source>
            <year>1985</year>
            <month>Jun</month>
            <day>06</day>
            <volume>312</volume>
            <issue>23</issue>
            <fpage>1473</fpage>
            <page-range>1473-9</page-range>
            <pub-id pub-id-type="pmid">2859524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon.</article-title>
            <source>Trends Neurosci</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>471</fpage>
            <page-range>471-482</page-range>
            <pub-id pub-id-type="pmid">35466006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monnier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dejager</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?</article-title>
            <source>Diabetes Care</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>4057</fpage>
            <page-range>4057-62</page-range>
            <pub-id pub-id-type="pmid">24170753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindmeyer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability.</article-title>
            <source>J Diabetes Sci Technol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>1262</fpage>
            <page-range>1262-1272</page-range>
            <pub-id pub-id-type="pmid">32806947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monnier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dejager</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?</article-title>
            <source>Diabetes Metab</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-7</page-range>
            <pub-id pub-id-type="pmid">25457475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirsch</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Kolaczynski</surname>
                <given-names>JW</given-names>
              </name>
              <collab>Insulin Aspart CSII/MDI Comparison Study Group</collab>
            </person-group>
            <article-title>Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.</article-title>
            <source>Diabetes Care</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>533</fpage>
            <page-range>533-8</page-range>
            <pub-id pub-id-type="pmid">15735183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inzucchi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bergenstal</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Diamant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrannini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tsapas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wender</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.</article-title>
            <source>Diabetologia</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-42</page-range>
            <pub-id pub-id-type="pmid">25583541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Sheu</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs.</article-title>
            <source>Ther Adv Chronic Dis</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>20406223211033674</fpage>
            <pub-id pub-id-type="pmid">34394904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monnier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dunseath</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-9</page-range>
            <pub-id pub-id-type="pmid">17259492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riddle</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ambrosius</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Brillon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Byington</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Malozowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Probstfield</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schnall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seaquist</surname>
                <given-names>ER</given-names>
              </name>
              <collab>Action to Control Cardiovascular Risk in Diabetes Investigators</collab>
            </person-group>
            <article-title>Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.</article-title>
            <source>Diabetes Care</source>
            <year>2010</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>983</fpage>
            <page-range>983-90</page-range>
            <pub-id pub-id-type="pmid">20427682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20266.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eeg-Olofsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cederholm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Zethelius</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gudbj&#x000f6;rnsd&#x000f3;ttir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eliasson</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).</article-title>
            <source>J Intern Med</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>268</volume>
            <issue>5</issue>
            <fpage>471</fpage>
            <page-range>471-82</page-range>
            <pub-id pub-id-type="pmid">20804517</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
